Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 6)
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
TUESDAY, Nov. 5, 2024 – Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover t...
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...
Semaglutide Linked to Reduced Risk for Alzheimer Diagnosis in T2DM
FRIDAY, Nov. 1, 2024 – For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic...
Ozempic, Wegovy Could Help Ease Knee Arthritis Pain
FRIDAY, Nov. 1, 2024 – The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of semaglutide – the active...
Semaglutide Beneficial for People With Obesity, Knee Osteoarthritis
THURSDAY, Oct. 31, 2024 – For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo,...
Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries
THURSDAY, Oct. 31, 2024 – A new guidance issued jointly by groups representing U.S. surgeons, anesthesiologists and gastroenterologists affirms that most people taking popular GLP-1 weight-loss meds...
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
TUESDAY, Oct. 29, 2024 – Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a...
Ozempic Curbs Kidney Disease in Obese People Without Diabetes
MONDAY, Oct. 28, 2024 – The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows. Patients taking semaglutide – the active agent in Ozempic and Wegovy – had...
Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds
FRIDAY, Oct. 25, 2024 – As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds....
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
THURSDAY, Oct. 24, 2024 – Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People with type 2 diabetes taking s...
Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
THURSDAY, Oct. 24, 2024 – For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed electric fields to induce natural cell death...
Greater Access to New Weight Loss Meds Could Save More Than 40,000 Lives Per Year
THURSDAY, Oct. 24, 2024 – Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year in the United States, a new study...
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
Weight-Loss Meds Like Wegovy, Ozempic Could Battle Alcoholism
THURSDAY, Oct. 17, 2024 – Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking...
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2